GLP-1疗法增加了内脏脂肪组织的代谢活性:来自阻塞性睡眠呼吸暂停的随机对照试验的经验教训
Cliona O'Donnell1,2, Odhrán Ryan3,4, Andrew E Hogan5
1Pulmonary and Sleep Disorders Unit, St. Vincent's University Hospital, Dublin, Ireland.
Obesity (Silver Spring, Md.)
|August 22, 2024
概括
类似葡萄糖-1 (GLP-1) 治疗增加了人体内脏脂肪组织 (VAT) 的代谢活性,有助于减肥. 这表明,在肥胖症治疗中,GLP-1类似物除了抑制食欲之外,还存在一种新的机制.
科学领域:
- 代谢研究的研究.
- 药理学 药理学是指药理学的学科.
- 肥胖药物 肥胖药物 肥胖药物
背景情况:
- 类似于葡萄糖类-1 (GLP-1) 的类似物是减肥的主要药物疗法,主要是通过减少能量摄入来减肥.
- 鼠类研究表明GLP-1类似物也可以通过增加内脏脂肪组织 (VAT) 的代谢活性来增强能量稳态.
- GLP-1类似物对人类增值税代谢活动的影响尚不清楚.
研究的目的:
- 研究GLP-1治疗对人类内脏脂肪组织 (VAT) 代谢活动的影响.
- 为了确定GLP-1治疗对VAT新陈代谢的影响是否与减肥相关.
- 探索GLP-1类似物在体重管理中的潜在作用机制.
主要方法:
- 一项概念验证研究涉及30名阻塞性睡眠呼吸暂停和肥胖症患者.
- 参与者被随机分配到GLP-1治疗,持续正气道压力 (CPAP) 或24周的组合.
- 18F-氧糖 (18F-FDG) PET-CT扫描测量了在基线和研究完成时的增值税代谢活性 (增值税目标与背景比率).
主要成果:
- GLP-1疗法显著增加了增值税目标与背景比率,表明增值税代谢活性增强.
- 持续的阳性气道压力 (CPAP) 疗法对VAT代谢活动没有显著影响.
- 观察到增值税代谢活动增加与体重减轻程度之间存在强烈的相关性.
结论:
- 这些发现支持了GLP-1疗法对人类的VAT代谢活动进行上调的假设,这有助于减肥.
- 这种增强的代谢活性代表了GLP-1类似物在肥胖治疗中的潜在作用机制.
- 需要对这一机制进行进一步的详细调查.
更多相关视频
08:30Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes
Published on: March 15, 2018
14.1K
09:41Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro
Published on: March 17, 2023
2.7K
相关概念视频
01:24Glucagon-like Receptor Agonists
306
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
306
01:23Dipeptidyl Peptidase 4 Inhibitors
179
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
179